Don Darkin - ResMed Insider

ResMed -- USA Stock  

USD 101.17  2.37  2.40%

President - Sleep-disordered Breathing Strategic Business Unit

Mr. Don Darkin is President innovation operations of Resmed Inc. Previously Mr. Darkin was president sleepdisordered breathing strategic business unit a position he began in May 2011 and senior vice president strategic business unit patient interfaces from July 2007 to May 2011. Before these positions Mr. Darkin held several senior roles within ResMed. He joined ResMed in August 1999 as vice president product development. In May 2005 he became director of operations in France for ventilation and subsequently served as vice president business divisions and senior vice president global product development. Before working at ResMed Mr. Darkin served as vice president of operations for Ambri Pty Ltd. Australia and vice president product development for Telectronics Medical Systems Australia and US. Mr. Darkin is identified as an inventor or coinventor on over 80 granted patents worldwide. Mr. Darkin was educated in the UK in mechanical engineering and has further professional management training from University of New South Wales and Massachusetts Institute of Technology.
Age: 61  President Since 2014      
858-836-5000  http://www.resmed.com

Don Darkin Latest Insider Activity

Management Efficiency

The company has Return on Asset of 9.1 % which means that on every $100 spent on asset it made $9.1 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.29 % implying that it generated $15.29 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 50.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 1.26 demonstrating that it may have difficulties to pay its financial commitments when the payables are due.

Similar Executives

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on New York Stock Exchange. It employs 6000 people.ResMed (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 6,000 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

ResMed Leadership Team

John Wareham, Director, MBA
Ronald Taylor, Director
Rob Douglas, President
Christopher Roberts, Director, MBA
Gary Pace, Director, Ph.D
Chris Roberts, Director, MBA
Robert Douglas, COO
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Brett Sandercock, CFO
Ron Taylor, Director
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA
Richard McHale, President
Donald Darkin, President

Stock Performance Indicators

Current Sentiment - RMD

ResMed Investor Sentiment
Greater number of Macroaxis users are at this time bullish on ResMed. What is your perspective on investing in ResMed? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Trending Equities

Currently Active Assets on Macroaxis
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago ago
Traded for 94.72
AOI   
 NYQ 
Purchased over 100 shares of
few hours ago ago
Traded for 24.75
REV   
 NYQ 
Purchased over 100 shares of
few hours ago ago
Traded for 22.75
FB   
 NMS 
Purchased few shares of
few hours ago ago
Traded for 166.69
VMW   
 NYQ 
Purchased over 20 shares of
few hours ago ago
Traded for 134.7
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago ago
Traded for 94.72
Additionally take a look at Your Equity Center. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.